Prescribing patterns and health-related quality of life in patients with chronic kidney disease: a cross-sectional study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20263537Keywords:
Chronic kidney disease, Drug prescribing, Polypharmacy, Health-related quality of life, RAND-36Abstract
Background: Chronic kidney disease (CKD) is associated with multimorbidity, polypharmacy, and impaired health-related quality of life (HRQoL). This study evaluated prescribing patterns using World Health Organization (WHO) core prescribing indicators and HRQoL using the RAND 36-item health survey 1.0 among patients with CKD.
Methods: A cross-sectional observational study was conducted among 162 adults with CKD in India. Prescribing patterns were assessed using WHO core prescribing indicators, and HRQoL was evaluated using the RAND-36 questionnaire. Associations between prescribing burden, patient characteristics, and physical component summary (PCS) and mental component summary (MCS) scores were analysed.
Results: The mean number of drugs per encounter was 12.77±3.68. Generic prescribing (38.64%) and essential medicines list (EML) adherence (61.57%) were below WHO benchmarks, while injection prescribing (29.23%) exceeded recommendations. Cardiovascular agents were the most frequently prescribed drug class (34.26%). HRQoL was impaired across all domains (PCS: 30.23±6.57; MCS: 35.30±5.30). Advancing CKD stage was associated with lower PCS and MCS (both p<0.001). Older age was associated with lower PCS (p<0.001), whereas higher medication burden was associated with lower MCS (p=0.034). Medication burden was also associated with greater comorbidity burden (p=0.007) and longer hospitalisation (p<0.001).
Conclusions: Patients with CKD experienced substantial polypharmacy, suboptimal adherence to WHO prescribing indicators, and impaired HRQoL. These findings highlight the need for rational prescribing, medication review, and routine patient-reported outcome assessment.
Metrics
References
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10518):2461-82.
Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):684-701. DOI: https://doi.org/10.1016/j.kint.2023.10.016
Hall RK, Kazancıoğlu R, Thanachayanont T, Wong G, Sabanayagam D, Battistella M, et al. Drug stewardship in chronic kidney disease to achieve effective and safe medication use. Nat Rev Nephrol. 2024;20(6):386-401. DOI: https://doi.org/10.1038/s41581-024-00823-3
Ofori-Asenso R. A closer look at the World Health Organization's prescribing indicators. J Pharmacol Pharmacother. 2016;7(1):51-4. DOI: https://doi.org/10.4103/0976-500X.179352
Pagels AA, Söderkvist BK, Medin C, Hylander B, Heiwe S. Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health Qual Life Outcomes. 2012;10:71. DOI: https://doi.org/10.1186/1477-7525-10-71
Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ. 1993;2:217-27. DOI: https://doi.org/10.1002/hec.4730020305
Kilipamwambu A, Bwire GM, Myemba DT, Njiro BJ, Majigo MV. WHO/INRUD core prescribing indicators and antibiotic utilization patterns among primary health care facilities in Ilala district, Tanzania. JAC Antimicrob Resist. 2021;3(2):dlab049. DOI: https://doi.org/10.1093/jacamr/dlab049
Seetharaman R, Advani M, Mali S, Pawar S. Drug utilization pattern in non-dialysis patients with diabetic nephropathy in a government-run tertiary care hospital in South Asia. J Basic Clin Physiol Pharmacol. 2023;34(3):371-381. DOI: https://doi.org/10.1515/jbcpp-2023-0003
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52. DOI: https://doi.org/10.1016/S0140-6736(16)32064-5
Al-Mansouri A, Hamad AI, Al-Ali FS, Ibrahim MIM, Kheir N, Al-Ziftawi NH, et al. Pill burden and its association with treatment burden among patients with advanced stages of chronic kidney disease. Saudi Pharm J. 2023;31(5):678-86. DOI: https://doi.org/10.1016/j.jsps.2023.03.008
Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-54. DOI: https://doi.org/10.1016/S2213-8587(19)30256-6
Fletcher BR, Damery S, Aiyegbusi OL, Anderson N, Calvert M, Cockwell P, et al. Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis. PLoS Med. 2022;19(4):e1003954. DOI: https://doi.org/10.1371/journal.pmed.1003954
Phillips T, Harris S, Aiyegbusi OL, Lucas B, Benavente M, Roderick PJ, et al. Potentially modifiable factors associated with health-related quality of life among people with chronic kidney disease: baseline findings from the NURTuRE-CKD cohort. Clin Kidney J. 2024;17(2):sfae010. DOI: https://doi.org/10.1093/ckj/sfae010
Adjeroh L, Brothers T, Shawwa K, Ikram M, Al-Mamun MA. The association between polypharmacy and health-related quality of life among non-dialysis chronic kidney disease patients. PLoS One. 2023;18(11):e0293912 DOI: https://doi.org/10.1371/journal.pone.0293912
Jasinska-Stroschein M. Effectiveness of pharmacist interventions in the management of patients with renal failure: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(18):11170. DOI: https://doi.org/10.3390/ijerph191811170
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Susheela Rani S., Imran Najir Khan, Anjana P., Aayushi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
